Matrixx Initiatives, Inc. (MTXX)

November 24, 2008

FeaturedProfiles.com Stock Pick: Matrixx Initiatives, Inc. (MTXX)

Stock Price: $14.77

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize the company's drug delivery systems. Its wholly-owned subsidiary, Zicam, LLC, markets and sells Zicam® and Nasal Comfort(TM) products in the cough and cold category.

MTXX also offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms.

MTXX is a perennial cold and flu season stock play and well known for that fact. MTXX dropped the last four trading days creating a buying opportunity to play this year's cold and flu season.

MTXX's over-the-counter cold and flu products are sold at several large national retailers including Wal-Mart, Walgreens, and CVS. Zicam is one of the top three cough, cold and allergy growth brands and its multi-symptom cold and flu products account for 45% of the company's retail sales growth.

MTXX has a attractive brand and sold distribution network in place. We believe MTXX will have another cold and flu season move.








			November 24, 2008 FeaturedProfiles.com Stock Pick: Matrixx Initiatives, Inc. (MTXX) Stock Price: $14.77 Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize the company's drug delivery systems. Its wholly-owned subsidiary, Zicam, LLC, markets and sells Zicam® and Nasal Comfort(TM) products in the cough and cold category. MTXX also offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms. MTXX is a perennial cold and flu season stock play and well known for that fact. MTXX dropped the last four trading days creating a buying opportunity to play this year's cold and flu season. MTXX's over-the-counter cold and flu products are sold at several large national retailers including Wal-Mart, Walgreens, and CVS. Zicam is one of the top three cough, cold and allergy growth brands and its multi-symptom cold and flu products account for 45% of the company's retail sales growth. MTXX has a attractive brand and sold distribution network in place. We believe MTXX will have another cold and flu season move.
			DISCLAIMER & RISK DISCLOSURE: FeaturedProfiles.com and SpeculatingStocks.com, Inc. and our affiliates ("our companies") are not registered investment advisers or broker/dealers. Our companies make no commitment that the purchase of securities of companies profiled or otherwise mentioned in our websites are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the possible lack of liquidity for their securities, investing in such securities is highly speculative and carries a high degree of risk. Never invest based solely on information from this Web site or our email alerts. Our FeaturedProfiles.com Newsletter is our free alert email membership. We profile selected companies on our site. These companies compensate SpeculatingStocks.com, Inc. for profile coverage. This compensation can be found in the disclosure on the bottom of the page of profiles. This Disclaimer & Risk Disclosure is also at the bottom of profiles. Specific questions on membership or profiles can be obtained by writing the FeaturedProfiles.com at: staff@featuredprofiles.com.